Condition: Colorectal Cancer · Sponsor: Caigang Liu
The purpose of this study is to assess the efficacy and safety of Cadonilimab (AK104) combined with chemotherapy and bevacizumab as first-line treatment for patients with RAS mutated or right sided-metastatic MSS colorectal cancer
This description comes directly from the study's public registry record.
Nan Niu, MD · 86+18940256668 · niunannancy@163.com
Caigang Liu, MD · 86+18940256668 · niunannancy@163.com
Always discuss trial participation with your own doctor first.
| Shengjing Hospital of China Medical University | Shenyang, Liaoning, China | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06566755